Infermedica a leading digital health company, specializing in AI-powered solutions for symptom analysis and patient triage announces the launch of its Medical Guidance Platform, with new modules and features designed to support the entire patient-care journey. The Medical Guidance Platform leverages the powerful clinically-validated technology behind Infermedica's successful symptom checker tool, and aims to provide personalized patient care from first symptoms to post-visit communication and treatment. In collaboration with its customers and partners, including Allianz, HonorHealth, Optum, Microsoft, LifeMD, Global Excel, Gothaer, and Sana Kliniken, Infermedica's solutions have been used by over 10 million people globally to triage patients to the right level of care. However, Infermedica's work to address the many challenges faced by healthcare is just beginning. It is estimated that up to five billion people will not have access to basic healthcare by 2030.

Artificial Intelligence (AI) is already being used in advanced medical settings and it has multiple applications including, wearable technology, precision medicine and virtual clinics. In some cases, it can even interpret test results more accurately than physicians. While most of us are just beginning to realise the full potential of AI, some entrepreneurs are way ahead. But how can they build trust with investors, what are the barriers for European startups and how can smaller companies get ahead? Pascal Lardier, VP for International Events and Media Content at HIMSS moderated the session around'AI Beyond the Buzz' at the HIMSS & Health 2.0 European Digital Conference, with the panel consisting of Neha Tanna, Investment Partner, Joyance Partners, Jorge Juan Fernández García, Director of Innovation, EIT Health, and Piotr Orzechowski, Founder & CEO, Infermedica in Poland.

Digital health startup Infermedica today nabbed $10.25 million to further develop its platform for symptom diagnosis. The company, which claims to have performed more than 6 million health checks to date, says it will put the proceeds toward R&D and international expansion in the U.S. and Germany. The demand for triaging solutions has risen substantially as the coronavirus pandemic rages on. Millions of patients wait at least two hours to see a provider, according to a study published by the U.S. Centers for Disease Control and Prevention (CDC). In response, tech giants including IBM, Facebook, and Microsoft have partnered with governments and private industry to roll out chatbot-based solutions, as have a number of startups.

Infermedica, a Poland and US-based company, has released a white-labeled symptom checker and triage platform after successful pilots with European healthcare insurance companies Allianz Partners, Dovera, and PZU. Infermedica uses artificial intelligence technology which has the potential to significantly improve quality of care, both from a provider and patient perspective. The application advises patients on what to do next when they feel unwell. After asking a series of diagnostic questions, Infermedica's AI suggests possible conditions and suitable actions to take. Infermedica estimates that typically up to 26% of patient cases are self-treatable, and a symptom checker can be used to prevent unnecessary visits by instead providing self-care or teleconsultations.